News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2025

31 October, 2025 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
23 October, 2025 Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on currently available clinical data News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
2 October, 2025 Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 183 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
2 October, 2025 Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares News Corporate Action Shares Issuance English Regulatory MAR IR Optional mfn-cus-disclaimer
21 August, 2025 Interim report Q2 2025 News English Regulatory MAR VPML Report Interim Q2 IR Optional
15 July, 2025 Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
6 May, 2025 Bulletin from Egetis Therapeutics’ Annual General Meeting 2025 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
30 April, 2025 Interim report Q1 2025 News English Regulatory MAR Report Interim Q1 IR Optional
11 April, 2025 Egetis Therapeutics’ Annual Report 2024 published News English Regulatory VPML Report Annual IR Optional
3 April, 2025 NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
26 February, 2025 Year-End Report January-December 2024 News English Regulatory MAR Report Interim Yearend IR Optional
13 February, 2025 European Commission approves Egetis’ Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional

2024

30 December, 2024 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
16 December, 2024 Issuance and repurchase of class C shares for incentive programs News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
12 December, 2024 Egetis receives positive CHMP opinion for Emcitate® (tiratricol) for the treatment of MCT8 deficiency News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
8 November, 2024 Interim report Q3 2024 News English Regulatory MAR Report Interim Q3 IR Optional
31 October, 2024 Egetis’ Nomination Committee for the 2025 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
31 October, 2024 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
28 October, 2024 Egetis Therapeutics publishes prospectus for admission to trading of shares on Nasdaq Stockholm News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
25 October, 2024 Bulletin from Egetis Therapeutics’ Extraordinary General Meeting 2024 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
4 October, 2024 Change in the Board of Directors of Egetis Therapeutics News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
30 September, 2024 NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
30 September, 2024 Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
30 September, 2024 Egetis Therapeutics announces the intention to carry out directed share issuances of approximately SEK 300 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
22 August, 2024 Interim report Q2 2024 News English Regulatory MAR VPML Report Interim Q2 IR Optional
Next

Calendar and upcoming reports

November 11-13, 2025
Stifel Annual Healthcare Conference (New York)

November 17, 2025
LifeSci Capital & Sofinnova, Growth & Innovation Summit (London)

Show more events

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]